baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

SINOPHARM GRP CO. H YC 1/ CNE100000FN7 /

6/4/2024 3:47:19 PM	Chg. +0.049	Volume	Bid3:47:19 PM	Ask3:47:19 PM	Market Capitalization	Dividend Y.	P/E Ratio
2.493EUR	+2.00%	- Turnover: -	2.493Bid Size: -	2.555Ask Size: -	3.44 bill.EUR	-	-

TeleTrader 11/9/2021 Sinopharm to test COVID drug in UAE, China

TeleTrader 10/11/2021 WHO recommends 3rd dose for over-60s after Sinovac, Sinopharm jab

TeleTrader 6/11/2021 China confirms Sinovac, Sinopharm shots approved for 3-17-y/os

TeleTrader 4/10/2021 Sinopharm's 3rd vaccine approved for clinical trials

TeleTrader 3/15/2021 Sinopharm, Sinovac researching effects of 3rd dose - report

TeleTrader 2/28/2021 Sinopharm Wuhan to make 100M vaccine doses per year

TeleTrader 2/24/2021 Sinopharm: 2nd vaccine 73% effective in trials

TeleTrader 1/29/2021 French official in favor of using Russia, China jabs

TeleTrader 1/29/2021 Hungary first in EU to approve Sinopharm's vaccine

TeleTrader 1/20/2021 Chinese vaccine makers applied to join COVAX - Beijing FM

TeleTrader 1/3/2021 Sinopharm, Sinovac deny vaccine smuggling claims

TeleTrader 12/31/2020 Sinopharm's COVID vaccine approved in China

TeleTrader 11/25/2020 Sinopharm seeks COVID vaccine authorization for public use

TeleTrader 8/18/2020 Sinopharm: Vaccine to be available by end of year

TeleTrader 7/16/2020 China's vaccine effective vs all COVID mutations - Sinopharm

TeleTrader 6/28/2020 Vaccine human trials were successful - China institute

TeleTrader 6/23/2020 China's COVID-19 vaccine to start phase 3 human trials

SINOPHARM GRP CO. H YC 1/ CNE100000FN7 /

If you wish to receive reply to your feedback, please provide your email address.